Vernakalant

ApprovedSmall molecule

AAdvanz Pharma

Vernakalant is one of 65 small molecule programs targeting Atrial Flutter. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atrial FlutterActive, not recruiting

Post-Operative Atrial FibrillationActive, not recruiting

Paroxysmal Atrial FibrillationActive, not recruiting

Atrial FibrillationActive, not recruiting

Atrial FlutterPhase 2/Phase 3

Active, not recruiting

Post-Operative Atrial FibrillationPhase 3

Active, not recruiting

Paroxysmal Atrial FibrillationApproved

Active, not recruiting

Atrial FibrillationPhase 3

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Vernakalant

AAdvanz Pharma

Approved

8 2

Calquence

AstraZeneca

Preclinical

1 3

Rituxan

Calan

4 5

Brukinsa

BBeOne Medicines

Preclinical

1 6

Imbruvica

PPharmacyclics LLC.

Preclinical

1 7

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 8

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 10

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atrial Fibrillation8 trials

A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)

Terminated·AAdvanz Pharma·Phase 3·NCT00989001·217 enrolled

A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)

Withdrawn·AAdvanz Pharma·Phase 4·NCT01627106

RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department

Completed·OOttawa Hospital Research Institute·Phase 4·NCT04485195·350 enrolled

Show 5 more trials

A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation

Completed·AAdvanz Pharma·Phase 3·NCT00668759·254 enrolled

Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence

Completed·AAdvanz Pharma·Phase 2·NCT00267930·221 enrolled

Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study

Completed·AAdvanz Pharma·Phase 2·NCT00526136·735 enrolled

Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation

Completed·AAdvanz Pharma·Phase 3·NCT00468767·356 enrolled

A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)

Completed·AAdvanz Pharma·Phase 3·NCT01174160·123 enrolled

Paroxysmal atrial fibrillation1 trial

Predictive Factors to Effectively Terminate Paroxysmal Atrial Fibrillation by Blocking Atrial Selective Ionic Currents

Completed·DDavid Filgueiras-Rama·Phase 4·NCT03005366·50 enrolled

Trial1 trial

Vernakalant Versus Flecainide: Atrial Contractility

Unknown status·MMaastricht University Medical Center·Phase 4·NCT01646281·70 enrolled

Post-Operative Atrial Fibrillation1 trial

Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients

Not yet recruiting·UUniversity of Calgary·Phase 3·NCT04748991·50 enrolled

Atrial Flutter1 trial

A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter

Completed·AAdvanz Pharma·Phase 2/3·NCT00476112·60 enrolled

1 more indication

Intravenous1 trial

Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)

Completed·CCorrevio International Sarl··NCT01370629·2,015 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Vernakalant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vernakalant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vernakalant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Advanz Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AAdvanz Pharma

Vernakalant

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atrial Fibrillation8 trials

Paroxysmal atrial fibrillation1 trial

Trial1 trial

Post-Operative Atrial Fibrillation1 trial

Atrial Flutter1 trial

Intravenous1 trial

References

Drug Info

Quick Facts

Related News